From Dow Jones & Company:

Moderna Inc.’s stock surged 13% after Oppenheimer upgraded the biotech to a buy with analysts expecting the company to have five products approved by 2026. Despite having only one approved product, its mRNA-based COVID-19 vaccine, Moderna has several promising products in its pipeline, including vaccines for flu and RSV. The company’s stock has dropped 40% over the last year due to COVID vaccine sales compression, but analysts are expecting sales to pick up again in 2025. Moderna’s gains also had a positive impact on other vaccine and drug makers’ stocks.

Analysts assigned the stock a $142 12- to 18-month price target, which is more than 30% upside over its current price.



Read more: Moderna’s stock soars after Oppenheimer upgrades to buy